UniPharma Co., Ltd. (TPEX:6621)
Taiwan · Delayed Price · Currency is TWD 11.45
0.00 (0.00%)
Sep 8, 2026, 12:51 PM CST
UniPharma Revenue
UniPharma had revenue of 39.74M TWD in the half year ending June 30, 2026, a decrease of -15.41%. This brings the company's revenue in the last twelve months to 83.87M, down -7.61% year-over-year. In the year 2025, UniPharma had annual revenue of 88.44M, down -5.36%.
Revenue (ttm)
83.87M
Revenue Growth
-7.61%
P/S Ratio
4.85
Revenue / Employee
n/a
Employees
34
Market Cap
406.49M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.44M | -5.01M | -5.36% |
| Dec 31, 2024 | 93.46M | -9.77M | -9.46% |
| Dec 31, 2023 | 103.22M | -24.89M | -19.43% |
| Dec 31, 2022 | 128.11M | 22.72M | 21.56% |
| Dec 31, 2021 | 105.39M | -33.25M | -23.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Prince Pharmaceutical | 1.22B |
| Excelsior Biopharma | 936.92M |
| Anxo Pharmaceutical | 878.88M |
| DV Biomed | 795.19M |
| GeneFerm Biotechnology | 664.94M |
| Winston Medical Supply | 632.80M |
| General Biologicals | 260.23M |
| Bioray Biotech | 207.17M |